Inhibikase Therapeutics, Inc. Common Stock (IKT) is a publicly traded Healthcare sector company. As of November 10, 2026, IKT trades at $1.57 with a market cap of $234.42M and a P/E ratio of -4.76. IKT moved -7.14% today. Year to date, IKT is -19.69%; over the trailing twelve months it is -1.51%. Its 52-week range spans $1.33 to $2.61. Analyst consensus is strong buy with an average price target of $4.88. Rallies surfaces IKT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for IKT combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $1.57 |
| Market Cap | $234.42M |
| P/E Ratio | -4.76 |
| EPS | $-0.43 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.61 |
| 52-Week Low | $1.33 |
| Volume | 392.45K |
| Avg Volume | 0 |
| Revenue (TTM) | $3.72M |
| Net Income | $-60.64M |
| Gross Margin | 0.00% |
4 analysts cover IKT: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $4.88.